Bone Marrow Mesenchymal Stem Cells: Key Insights and Functions

Bone marrow mesenchymal stem cells are multipotent cells nestled within the marrow of your bones, capable of developing into bone, cartilage, or fat tissue depending on the signals they receive. Their therapeutic promise, though, rests less on that shape-shifting ability than on something researchers only fully appreciated in recent decades: these cells release a rich cocktail of signaling molecules that can dampen inflammation, encourage blood vessel growth, and nudge damaged tissues toward repair. That dual nature, part builder and part pharmacist, has made them one of the most intensively studied cell types in regenerative medicine.

How Scientists Identify Them

Bone marrow contains a mix of cell types, and mesenchymal stem cells (often abbreviated MSCs) make up only a small fraction. Isolating them starts with a practical trick: when you plate bone marrow cells on a culture dish, MSCs stick to the plastic surface while most blood-forming cells wash away. But adhesion alone is not enough to confirm what you have. In 2006, the International Society for Cell Therapy laid out minimum criteria that a cell must meet to qualify as an MSC. It must carry three surface proteins, designated CD73, CD90, and CD105, while lacking markers associated with blood cells, such as CD34 and CD45.¹ A scoping review of published studies found that CD105 appeared in about 83% of in vitro characterization experiments, CD90 in 75%, and CD73 in 52%, along with additional markers like CD44, CD166, and STRO-1 used for finer distinctions.²

These markers are useful for sorting cells in the lab, but researchers have noted that CD73, CD90, and CD105 do not actually represent “stemness” in the strict biological sense. They are shared by various connective tissue cell types, including ordinary fibroblasts. That overlap is one reason the identity of MSCs remains a topic of lively debate, a point we will return to later.

The Bone Marrow Niche

Inside living bone marrow, MSCs do not float freely. They occupy a specific neighborhood known as the perivascular niche, meaning they cluster around blood vessels, often near the spongy trabecular bone at the ends of long bones.³ This location is not accidental. By wrapping around blood vessels alongside endothelial cells, MSCs help create a microenvironment that supports the blood-forming (hematopoietic) stem cells the marrow is better known for. The niche is a two-way street: the surrounding tissue feeds MSCs oxygen and chemical cues, while MSCs maintain the scaffolding and signaling that keep blood cell production running smoothly.

Choosing a Cell Fate

The classic demonstration of MSC “multipotency” is a lab assay where cells are coaxed into becoming bone-forming osteoblasts, cartilage-producing chondrocytes, or fat-storing adipocytes. Several signaling pathways govern which fate wins. The Wnt pathway and the bone morphogenetic protein (BMP) branch of the TGF-β pathway are especially well studied for steering MSCs toward bone and cartilage.⁴ What makes the system particularly interesting is that bone and fat fates are locked in a tug-of-war. Molecular switches that push a cell toward becoming an osteoblast actively suppress the fat program, and vice versa. A transcription factor called Runx2 promotes bone, while PPARγ promotes fat, and the two pathways cross-inhibit each other through a web of additional signals including hedgehog proteins, fibroblast growth factors, and insulin-like growth factors.⁵

This competitive balance has real consequences for aging and disease. When the balance tips toward fat at the expense of bone, the marrow cavity fills with adipocytes while bone density drops, a pattern seen in osteoporosis.

How Stiffness Steers the Decision

Chemical signals are not the only cues MSCs respond to. In a landmark study, researchers seeded MSCs onto gel surfaces of varying stiffness and found that cells on soft gels resembling brain tissue turned toward a nerve-like fate, cells on medium-stiffness gels resembling muscle became muscle-like, and cells on rigid gels resembling bone became osteogenic. After several weeks, the cells committed so firmly that adding chemical induction factors could no longer override the choice.⁶ The mechanism involves cytoskeletal tension: a stiffer surface makes the cell’s internal scaffolding pull harder, and that mechanical information travels to the nucleus to change gene expression.⁷

More recent work has identified specific small RNA molecules, such as miR-99b, whose levels rise as the surrounding material gets stiffer. This microRNA then targets a growth-regulating pathway inside the cell, tipping the balance between fat and bone differentiation in response to mechanical input.⁸ For tissue engineers, the practical takeaway is straightforward: the scaffold you build matters as much as the growth factors you add.

Immune System Modulation

One of the most clinically relevant properties of bone marrow MSCs is their ability to dial down immune responses. They interact with cells from both the innate and adaptive arms of the immune system, broadly dampening inflammatory reactions.⁹ Specifically, MSCs can slow the proliferation of T cells, B cells, and natural killer cells, shift the behavior of dendritic cells, and encourage the expansion of regulatory T cells, which are the immune system’s own peacekeepers. They accomplish this through a mix of direct cell-to-cell contact, secreted molecules, and tiny membrane-wrapped packages called extracellular vesicles.¹⁰

This immunomodulatory talent is context-dependent. MSCs do not simply shut down every immune response they encounter; they sense the inflammatory environment and adjust their output accordingly. In a highly inflamed setting, they tend to suppress; in a low-inflammation setting, their behavior can differ. That responsiveness is part of what makes them attractive for treating autoimmune and transplant-related conditions.

Signaling Molecules and Exosomes

For years, the assumption was that MSC therapy worked because transplanted cells physically replaced damaged tissue. The evidence increasingly points elsewhere. Much of the benefit comes from paracrine activity: the cells release growth factors, anti-inflammatory proteins, and other signaling molecules into the surrounding space, and those secreted factors do the heavy lifting of tissue regeneration.¹¹

A particularly active area of research involves exosomes, tiny vesicles that MSCs shed into their surroundings. These nanoscale packages carry microRNAs and other bioactive cargo that can be taken up by neighboring cells, effectively reprogramming the recipient cell’s gene expression. In preclinical models, MSC-derived exosomes have been shown to reduce fibrosis, shift immune cell behavior, and promote new blood vessel formation.¹² In cardiac research, stem cell-derived exosomes loaded with microRNAs are being explored as a cell-free therapy option, one that could deliver regenerative benefits without the complications of transplanting living cells.¹³

How MSCs Find Injured Tissue

When tissue is damaged, it releases distress signals into the bloodstream. One of the best-characterized homing signals involves a molecule called SDF-1 (also known as CXCL12) and its receptor CXCR4, which sits on the surface of MSCs. Injured tissues ramp up SDF-1 production, and MSCs expressing CXCR4 migrate toward that chemical gradient like a moth to a flame. Blocking this axis with a drug called AMD3100 significantly reduces the number of MSCs that reach damaged tissue and weakens their therapeutic effect.¹⁴ The same pathway has been demonstrated in bone defect models, where overexpression of SDF-1 at the injury site recruited more MSCs and boosted the production of bone-forming proteins.¹⁵

Clinical Applications Under Investigation

Bone marrow MSCs have entered clinical trials for a wide range of conditions. Three areas stand out for the breadth of evidence accumulated so far.

Graft-Versus-Host Disease

After a bone marrow transplant from a donor, the transplanted immune cells sometimes attack the recipient’s own tissues, a condition called graft-versus-host disease (GvHD). MSCs, with their immunosuppressive toolkit, have been tested as a treatment. Clinical studies have generally found them safe and well tolerated, with encouraging response rates, though those rates have varied across trials.¹⁶ Even the extracellular vesicles shed by MSCs appear to help: in a mouse model of acute GvHD, infusion of BM-MSC-derived vesicles prolonged survival, reduced organ damage, and suppressed the shift of T cells from a resting to an aggressive state.¹⁷

Osteoarthritis and Cartilage Repair

Bone marrow MSCs have been extensively studied for knee osteoarthritis, where the goal is to slow cartilage breakdown and reduce joint inflammation.¹⁸ In this setting, MSCs appear to work through a combination of paracrine anti-inflammatory signaling and some direct contribution to cartilage regeneration, though the relative importance of each mechanism is still being sorted out.¹⁹

Heart Repair After a Heart Attack

After a myocardial infarction, regions of the heart muscle die and are replaced by scar tissue. MSC transplantation has been tested as a way to limit that damage. Animal and early human studies suggest that MSCs secrete growth factors that activate resident cardiac stem cells, promote new blood vessel formation, reduce inflammation, and limit harmful remodeling of the heart wall.²⁰ Their low immunogenicity, meaning they do not strongly trigger the recipient’s immune system, makes them practical candidates for transplantation across different individuals.²¹

Bone Marrow vs. Other Tissue Sources

Bone marrow is the classic source for MSCs, but the cells can also be harvested from adipose (fat) tissue, umbilical cord blood, and the cord tissue itself. The question of which source is “best” does not have a clean answer because each has trade-offs. A comparative study found that the success rate of isolating MSCs was 100% from bone marrow and adipose tissue, but only about 63% from umbilical cord blood. Cord blood MSCs, however, could be cultured for the longest time and proliferated the fastest, whereas bone marrow MSCs had the shortest culture lifespan and lowest proliferation rate. And cord blood MSCs, in a notable limitation, showed no ability to differentiate into fat cells.²²

Despite these functional differences, all three sources produce cells that look similar under the microscope and share the same standard surface markers.²³ When researchers compared adipose-derived and cord-derived MSCs head to head, both efficiently differentiated into bone, cartilage, fat, and nerve-like structures.²⁴ The gene expression profiles, however, differ depending on the tissue of origin, suggesting that even cells that look the same on the surface carry internal differences shaped by where they grew up.

The Cancer Complication

The same SDF-1/CXCR4 homing pathway that guides MSCs to injured tissue has a darker side. Leukemia cells use the same axis to migrate into protective niches within the bone marrow, where contact with stromal cells shields them from chemotherapy. Higher CXCR4 expression on leukemia cells has been associated with worse outcomes in several forms of the disease.²⁵ In acute myeloid leukemia, MSCs play a genuinely double-edged role. They can support leukemia cell survival, proliferation, and drug resistance through secreted factors and direct contact, but they have also been observed to trigger cancer cell death and cell cycle arrest under certain conditions.²⁶

Research into B-cell acute lymphoblastic leukemia has shown that a stress-response protein called Nrf2 becomes highly expressed in MSCs from patients with the disease. When Nrf2 is overexpressed, MSCs activate the SDF-1/CXCR4 axis more strongly, promoting leukemia cell migration and invasion into organs outside the marrow, which in mouse models significantly shortened survival.²⁷ Understanding how the bone marrow niche is co-opted by cancer cells is now a major focus for developing therapies that disrupt those protective interactions.

Preparing Cells Before Transplant

Cells pulled from the body and expanded in a dish do not always perform well once transplanted back into a hostile, oxygen-starved injury site. Researchers have developed various “priming” strategies to toughen them up beforehand, including exposure to cytokines, growth factors, pharmacological drugs, and specialized biomaterials.²⁸

Hypoxic preconditioning, where cells are briefly exposed to low-oxygen conditions before transplantation, is one of the most studied approaches. Brief episodes of low oxygen significantly increase survival, proliferation, and the capacity of cells to differentiate after they are engrafted.²⁹ Under hypoxia, MSCs also ramp up production of secreted factors including a key driver of blood vessel growth, essentially turning up their paracrine signaling volume before they are placed into the patient.³⁰ The logic echoes a well-known phenomenon in organ physiology, where brief episodes of reduced blood flow protect against a subsequent severe shortage.

Genetic Stability During Lab Expansion

Clinical applications typically require far more MSCs than a single bone marrow aspirate provides, so cells must be expanded through many rounds of division in culture. This expansion raises safety concerns. One of the most relevant is genetic stability: cells that divide many times can accumulate DNA damage, and if that damage is not repaired or detected, it could theoretically lead to malignant transformation.³¹

A study of mouse bone marrow MSCs in long-term culture found that the cells gradually lost their ability to recognize and repair DNA double-strand breaks. As culture time increased, the DNA damage response became sluggish, repair slowed, and the number of unrepaired breaks rose. In parallel, chromosomal instability after cell division increased, as measured by a higher frequency of micronuclei, small DNA-containing structures that form when chromosomes are improperly segregated.³² At present, karyotype analysis is the standard safety check for clinical-grade MSCs, but these findings suggest that subtler DNA alterations may slip through conventional screening.

Metabolic Shifts During Differentiation

Undifferentiated MSCs tend to rely heavily on glycolysis, the metabolic pathway that breaks down glucose without requiring much oxygen. They maintain high levels of a regulatory protein called HIF-1 that supports this glycolytic state. When MSCs begin to differentiate into osteoblasts, they switch on mitochondrial oxidative phosphorylation while downregulating HIF-1, effectively rerouting their energy production as part of the commitment to a bone-forming identity.³³

The metabolic story varies by lineage. MSCs pushed toward cartilage show a steep drop in oxygen consumption over the first three weeks of culture, settling into a predominantly glycolytic metabolism. By contrast, MSCs undergoing osteogenic differentiation maintain a steady oxygen consumption rate throughout the same period, consistent with a more oxidative energy strategy.³⁴ These metabolic fingerprints are more than curiosities. They influence how cells perform in different environments and may offer targets for steering differentiation in therapeutic contexts.

When BM-MSCs Malfunction

If bone marrow MSCs are important for maintaining healthy tissue, it follows that their dysfunction can contribute to disease. Osteoporosis is a prime example. In mouse models of estrogen-deficiency osteoporosis, MSCs from the bone marrow showed reduced ability to form bone and an increased tendency to form fat, along with impaired immunoregulatory function.³⁵ Multiple lines of evidence now indicate that osteoporotic MSCs carry defective internal signals that shift their differentiation bias toward fat at the expense of bone.³⁶ This is consistent with the competitive balance between osteoblast and adipocyte pathways described earlier: when intrinsic signaling defects tip the balance, the clinical result is weaker bones and marrow filled with fat cells.

The Naming Controversy

The term “mesenchymal stem cell” is itself contested, and the dispute is not purely academic. Arnold Caplan, who helped popularize the term in the 1990s, later argued publicly that it should be changed to “Medicinal Signaling Cells.” His reasoning was that calling them stem cells implies they work by turning into new tissue, when the evidence increasingly shows they work by secreting bioactive molecules that stimulate the patient’s own resident stem cells to do the rebuilding.³⁷ The concern is practical: unscrupulous clinics market unregulated “stem cell” injections on the implied promise that the cells will grow into fresh tissue. A more accurate name could undercut that marketing.

Other researchers go further, arguing that the entire concept of a universal “MSC” should be abandoned. MSCs isolated from different tissues do not share a common embryonic origin, are not a single lineage, and do not differentiate outside of their tissue-specific capabilities when tested with rigorous assays. What ties them together is mainly that they are all fibroblast-like cells that stick to plastic and express the same surface markers, which may reflect shared fibroblastic properties rather than shared stem cell identity.³⁸ This is not a settled debate, and the resolution matters for how clinical trials are designed, regulated, and interpreted.

MSC Membranes as Drug Delivery Vehicles

One of the more creative applications of MSC biology has nothing to do with transplanting living cells. Researchers have begun isolating MSC cell membranes and wrapping them around synthetic nanoparticles, creating hybrid vehicles sometimes called “nanoghosts.” The logic is simple: the nanoparticle carries the drug, while the MSC membrane provides the surface proteins that allow the particle to home to injured or diseased tissue and avoid immune clearance.³⁹

In one approach, bone marrow MSCs were genetically engineered to overexpress the CXCR4 homing receptor before their membranes were harvested and coated onto fluorescent nanoparticles. The resulting particles actively migrated toward injured cartilage cells in laboratory tests, effectively combining the targeting ability of MSCs with the drug-carrying capacity of nanotechnology.⁴⁰ This strategy sidesteps many of the safety and manufacturing challenges associated with live cell therapies while retaining the biological targeting these cells evolved to perform.